Alternative clinical approaches to the treatment of pruritus related with canine atopic dermatitis

Year 2023, , 40 - 49, 30.04.2023

Deniz Zeynep Telci , Semih İzmirli , M. Erman Or , Banu Dokuzeylül

https://doi.org/10.30704/http-www-jivs-net.1243160

Cited By: 1

Abstract

Canine atopic dermatitis (CAD) is a genetically inheritable, inflammatory and pruritic skin disease with characteristic clinical features, most commonly associated with IgE antibodies to environmental allergens. Itching is the most prominent clinical finding. Depending on the allergens involved, seasonal or non-seasonal pruritus may occur.
In the first active phase of pruritus treatment, which consists of two stages, acute exacerbations should be controlled by drugs with active ingredients such as corticosteroids, oclacitinib, lokivetmab, etc. In the proactive pruritus treatment, it is aimed to prevent exacerbations and prolong the pruritus-free period with maintenance treatment. For this purpose, in addition to active phase of the therapy, different treatment options such as cyclosporine, tacrolimus, antihistamines, essential fatty acids, Palmitoylethanolamide (PEA), topical drugs and shampoos can be used to repair the skin barrier.
Due to the side effects and costs of the drugs used in the treatment of pruritus in atopic dermatitis, researches on alternative treatment methods are still continuing. Applications such as mesenchymal stem cell therapy, recombinant canine gamma-interferon, luteolin, vitamin D, vitamin E, lactoferricin/verbascoside, mastinib, cannabidiol (CBD), probiotics and vaccination against IL-31 are the alternative treatment options for atopic dermatitis in dogs. However, more studies are needed before their inclusion in our routine clinical practices and added to the guidelines. In this review, it is aimed to provide information about new treatments used for pruritus in CAD and to encourage their use in routine veterinary clinical practice.

Keywords

Canine atopic dermatitis (CAD), pruritus, alternative treatment methods, dog

References

• Abba, C., Mussa, P. P., Vercelli, A., & Raviri, G. (2005). Essential fatty acids supplementation in different‐stage atopic dogs fed on a controlled diet. Journal of Animal Physiology and Animal Nutrition, 89(3‐6), 203-207.
• Ahlstrom, L. A., Mason, K. V., & Mills, P. C. (2010). Barazone decreases skin lesions and pruritus and increases quality of life in dogs with atopic dermatitis: a randomized, blinded, placebo‐controlled trial. Journal of Veterinary Pharmacology and Therapeutics, 33(6), 573-582.
• Bachmann, M. F., Zeltins, A., Kalnins, G., Balke, I., Fischer, N., Rostaher, A., & Favrot, C. (2018). Vaccination against IL-31 for the treatment of atopic dermatitis in dogs. Journal of Allergy and Clinical Immunology, 142(1), 279-281.
• Bensignor, E., & Olivry, T. (2005). Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. Veterinary Dermatology, 16(1), 52-60. Belvedere, R., Pessolano, E., Novizio, N., Tosco, A., Eletto, D., Porta, A., & Petrella, A. (2021). The promising pro-healing role of the association of mesoglycan and lactoferrin on skin lesions. European Journal of Pharmaceutical Sciences, 163, 105886.
• Biasibetti, E., Bruni, N., Bigliati, M., Capucchio, M. T. (2018) Lactoferricin/verbascoside topical emulsion: a possible alternative treatment for atopic dermatitis in dogs, Natural Product Research, 32(17), 2107-2110
• Bravo-Monsalvo, A., Vázquez-Chagoyán, J., Gutiérrez, L., & Sumano, H. (2008). Clinical efficacy of neural therapy for the treatment of atopic dermatitis in dogs. Acta Veterinaria Hungarica, 56(4), 459-469.
• Cadot, P., Hensel, P., Bensignor, E., Hadjaje, C., Marignac, G., Beco, L., & Hermine, O. (2011). Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double‐blind, placebo‐controlled phase 3 trial. Veterinary Dermatology, 22(6), 554-564.
• Carlotti, D. N., Boulet, M., Ducret, J., Machicote, G., Jasmin, P., Rème, C. A., & Albouy, M. (2009). The use of recombinant omega interferon therapy in canine atopic dermatitis: a double‐blind controlled study. Veterinary Dermatology, 20(5‐6), 405-411.
• Cosgrove, S. B., Cleaver, D. M., King, V. L., Gilmer, A. R., Daniels, A. E., Wren, J. A., & Stegemann, M. R. (2015). Long‐term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Veterinary Dermatology, 26(3), 171-e35.
• Cosgrove, S. B., Wren, J. A., Cleaver, D. M., Walsh, K. F., Follis, S. I., King, V. I., ... & Stegemann, M. R. (2013). A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the J anus kinase inhibitor oclacitinib (Apoquel®) in client‐owned dogs with atopic dermatitis. Veterinary Dermatology, 24(6), 587-e142.
• Crowell-Davis, S. L., & Murray, T. (2006). Tricyclic antidepressants. Veterinary Psychopharmacology, 179-206. Daigle, J., Moussy, A., Mansfield, C. D., & Hermine, O. (2010). Masitinib for the treatment of canine atopic dermatitis: a pilot study. Veterinary Research Communications, 34(1), 51-63.
• Daltro, S. R. T., Meira, C. S., Santos, I. P., Ribeiro dos Santos, R., & Soares, M. B. P. (2020). Mesenchymal stem cells and atopic dermatitis: a review. Frontiers in Cell and Developmental Biology, 8, 326.
• DeBoer, D. J., Schafer, J. H., Salsbury, C. S., Blum, J. R., Beale, K. M., Vitale, C. B., & McArthur, T. R. (2002). Multiple-center study of reduced-concentration triamcinolone topical solution for the treatment of dogs with known or suspected allergic pruritus. American Journal of Veterinary Research, 63(3), 408-413.
• De Caro Martins, G., da Costa-Val, A.P., Coura, F.M., Diamantino, G.M.L., Nogueira, M.M., de Oliveira Melo-Junior, O.A., Giunchetti, R.C., da Silveira-Lemos, D. and Melo, M.M. (2022), Immunomodulatory effect of long-term oclacitinib maleate therapy in dogs with atopic dermatitis. Veterinary Dermatology, 33, 142e40.
• Denti, D., Caldin, M., Ventura, L. and De Lucia, M. (2022), Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs. Veterinary Dermatology 33, 149-e42
• Dodman, N. H., Shuster, L., Nesbitt, G., Weissman, A., Lo, W. Y., Chang, W. W., & Cottam, N. (2004). The use of dextromethorphan to treat repetitive self‐directed scratching, biting, or chewing in dogs with allergic dermatitis. Journal of Veterinary Pharmacology and Therapeutics, 27(2), 99-104.
• Eichenseer, M., Johansen, C., & Mueller, R. S. (2013). Efficacy of dimetinden and hydroxyzine/chlorpheniramine in atopic dogs: a randomised, controlled, double‐blinded trial. Veterinary Record, 173(17), 423-423.
• Elkholly, D. A., Brodbelt, D. C., Church, D. B., Pelligand, L., Mwacalimba, K., Wright, A. K., & O'Neill, D. G. (2020). Side effects to systemic glucocorticoid therapy in dogs under primary veterinary care in the UK. Frontiers in veterinary science, 7, 515.
• Enciso, N., Amiel, J., Pando, J., & Enciso, J. (2019). Multidose intramuscular allogeneic adipose stem cells decrease the severity of canine atopic dermatitis: A pilot study. Veterinary world, 12(11), 1747. Kaya, E. (2020). Topikal takrolimusun veteriner dermatolojide kullanımı . Cumhuriyet Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 5(1), 30-37.
• Fujimura, M., Ishimaru, H., & Nakatsuji, Y. (2014). Fluoxetine (SSRI) treatment of canine atopic dermatitis: a randomized, double-blind, placebo-controlled, crossover trial. Polish journal of veterinary sciences, 17(2), 371-373.
• Gamble, L. J., Boesch, J. M., Frye, C. W., Schwark, W. S., Mann, S., Wolfe, L., Brown, H., Berthelsen, E. S., & Wakshlag, J. J. (2018). Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Frontiers in veterinary science, 5, 165.
• Gendrisch, F., Esser, P. R., Schempp, C. M., & Wölfle, U. (2021). Luteolin as a modulator of skin aging and inflammation. Biofactors, 47(2), 170-180.
• Gortel, K. (2018). An embarrassment of riches: an update on the symptomatic treatment of canine atopic dermatitis. Canadian Veterinary Journal, 59(9), 1013.
• Gugliandolo, E, Palma, E, Cordaro, M, et al. 2020, Canine atopic dermatitis: Role of luteolin as new natural treatment. Veterinary Medicine and Science, 6, 926-932.
• Hensel, P., Santoro, D., Favrot, C., Hill, P., & Griffin, C. (2015). Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification. BMC Veterinary Research, 11, 196
• Iwasaki, T., & Hasegawa, A. (2006). A randomized comparative clinical trial of recombinant canine interferon‐γ (KT‐100) in atopic dogs using antihistamine as control. Veterinary Dermatology, 17(3), 195-200.
• Kaur, G., Ramirez, A., Xie, C., Clark, D., Dong, C., Maki, C., ... & Hao, J. (2022). A double-blinded placebo-controlled evaluation of adipose-derived mesenchymal stem cells in treatment of canine atopic dermatitis. Veterinary Research Communications, 46(1), 251-260.
• Kim, H., Rather, I. A., Kim, H., Kim, S., Kim, T., Jang, J., ... & Park, Y. H. (2015). A double-blind, placebo controlled-trial of a probiotic strain Lactobacillus sakei probio-65 for the prevention of canine atopic dermatitis. Journal of Microbiology and Biotechnology, 25(11), 1966-1969.
• Klinger, C. J., Hobi, S., Johansen, C., Koch, H. J., Weber, K., & Mueller, R. S. (2018). Vitamin D shows in vivo efficacy in a placebo‐controlled, double‐blinded, randomised clinical trial on canine atopic dermatitis. Veterinary Record, 182(14), 406-406.
• Klotz, D., Baumgärtner, W., & Gerhauser, I. (2017). Type I interferons in the pathogenesis and treatment of canine diseases. Veterinary Immunology and Immunopathology, 191, 80-93.
• Kogan, L., Schoenfeld-Tacher, R., Hellyer, P., & Rishniw, M. (2019). US veterinarians' knowledge, experience, and perception regarding the use of cannabidiol for canine medical conditions. Frontiers in Veterinary Science, 338.
• Kotnik, T. (2018). Vitamin D therapy in canine atopic dermatitis. Veterinary Record, 182(14), 403. Lee, S., Yun, T., Koo, Y., Chae, Y., Lee, D., Choi, D., ... & Kang, B. T. (2021). Clinical efficacy of oclacitinib and lokivetmab in dogs with canine atopic dermatitis. Journal of Veterinary Clinics, 38(3), 127-134.
• Litzlbauer, P., Weber, K., & Mueller, R. S. (2014). Oral and subcutaneous therapy of canine atopic dermatitis with recombinant feline interferon omega. Cytokine, 66(1), 54-59.
• Loewinger, M., Wakshlag, J. J., Bowden, D., Peters‐Kennedy, J., & Rosenberg, A. (2022). The effect of a mixed cannabidiol and cannabidiolic acid based oil on client‐owned dogs with atopic dermatitis. Veterinary Dermatology.33(4), 329–e77.
• Lopes, N. L., Campos, D. R., Machado, M. A., Alves, M. S. R., de Souza, M. S. G., da Veiga, C. C. P., ... & Fernandes, J. I. (2019). A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats. BMC Veterinary Research, 15(1), 1-9.
• Lourenço, A.M., Schmidt, V., São Braz, B., Nóbrega, D., Nunes, T., Duarte-Correia, J.H., Matias, D., Maruhashi, E., Rème, C.A. and Nuttall, T. (2016), Efficacy of proactive long-term maintenance therapy of canine atopic dermatitis with 0.0584% hydrocortisone aceponate spray: a double-blind placebo controlled pilot study. Veterinary Dermatology. 27, 88-e25
• McFadden, R. A., Heinrich, N. A., Haarstad, A. C., & Tomlinson, D. J. (2017). A double‐blinded, randomized, controlled, crossover evaluation of a zinc methionine supplement as an adjunctive treatment for canine atopic dermatitis. Veterinary Dermatology, 28(6), 569-e138.
• McGrath, S., Bartner, L. R., Rao, S., Packer, R. A., & Gustafson, D. L. (2019). Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. Journal of the American Veterinary Medical Association, 254(11), 1301-1308.
• Marchegiani A, Fruganti A, Spaterna A, Dalle Vedove E, Bachetti B, Massimini M, Di Pierro F, Gavazza A, Cerquetella M., (2020), Impact of nutritional supplementation on canine dermatological disorders. Veterinary Sciences.7(2), 38.
• Marsella, R. (2009). Evaluation of Lactobacillus rhamnosus strain GG for the prevention of atopic dermatitis in dogs. American Journal of Veterinary Research, 70(6), 735-740.
• Michels, G. M., Walsh, K. F., Kryda, K. A., Mahabir, S. P., Walters, R. R., Hoevers, J. D., & Martinon, O. M. (2016). A blinded, randomized, placebo‐controlled trial of the safety of lokivetmab (ZTS‐00103289), a caninized anti‐canine IL‐31 monoclonal antibody in client‐owned dogs with atopic dermatitis. Veterinary Dermatology, 27(6), 505-e136.
• Mogi, C., Yoshida, M., Kawano, K., Fukuyama, T., & Arai, T. (2022). Effects of cannabidiol without delta-9-tetrahydrocannabinol on canine atopic dermatitis: A retrospective assessment of 8 cases. Canadian Veterinary Journal, 63(4), 423.
• Moyaert, H., Van Brussel, L., Borowski, S., Escalada, M., Mahabir, S. P., Walters, R. R., & Stegemann, M. R. (2017). A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client‐owned dogs with atopic dermatitis. Veterinary Dermatology, 28(6), 593-e145.
• Mueller, R. S., Nuttall, T., Prost, C., Schulz, B., & Bizikova, P. (2021). Treatment of the feline atopic syndrome–a systematic review. Veterinary Dermatology, 32(1), 43-e8.
• Mueller, R. S., & Hartmann, K. (2021). Interferon therapies in small animals. Veterinary Journal, 271, 105648. Nam, E. H., Park, S. H., Jung, J. Y., Han, S. H., Youn, H. Y., Chae, J. S., & Hwang, C. Y. (2012). Evaluation of the effect of a 0.0584% hydrocortisone aceponate spray on clinical signs and skin barrier function in dogs with atopic dermatitis. Journal of Veterinary Science, 13(2), 187–19
• Nole, K. L. B., Yim, E., & Keri, J. E. (2014). Probiotics and prebiotics in dermatology. Journal of the American Academy of Dermatology, 71(4), 814-821.
• Noli C., Foster A., Rosenkrantz W., (2014). Veterinary Allergy. Bristol, England: John Wiley & Sons
• Noli, C., Della Valle, M.F., Miolo, A., Medori, C., Schievano, C. and (2015), Efficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre study. Veterinary Dermatology, 26, 432-e101
• Noli, C., Matricoti, I., & Schievano, C. (2019). A double‐blinded, randomized, methylprednisolone‐controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood‐induced hypersensitivity dermatitis. Veterinary Dermatology, 30(2), 110-e30.
• Nuttall, T., Mueller, R., Bensignor, E., Verde, M., Noli, C., Schmidt, V., & Rème, C. (2009). Efficacy of a 0.0584% hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo‐controlled trial. Veterinary Dermatology, 20(3), 191-198.
• Nuttall, T. J., McEwan, N. A., Bensignor, E., Cornegliani, L., Löwenstein, C., & Rème, C. A. (2012). Comparable efficacy of a topical 0.0584% hydrocortisone aceponate spray and oral ciclosporin in treating canine atopic dermatitis. Veterinary Dermatology, 23(1), 4-e2.
• Ohmori, K., Tanaka, A., Makita, Y., Takai, M., Yoshinari, Y., & Matsuda, H. (2010). Pilot evaluation of the efficacy of shampoo treatment with ultrapure soft water for canine pruritus. Veterinary dermatology, 21(5), 477-483. Ohshima‐Terada, Y., Higuchi, Y., Kumagai, T., Hagihara, A., & Nagata, M. (2015). Complementary effect of oral administration of L actobacillus paracasei K 71 on canine atopic dermatitis. Veterinary dermatology, 26(5), 350-e75. Olivry, T., DeBoer, D.J., Favrot, C. et al. (2015),Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res 11, 210
• Olivry, T., DeBoer, D.J., Favrot, C., Jackson, H.A., Mueller, R.S., Nuttall, T., Prélaud, P. and (2010), Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Veterinary Dermatology, 21: 233-248
• Olivry, T., Foster, A. P., Mueller, R. S., McEwan, N. A., Chesney, C., & Williams, H. C. (2010). Interventions for atopic dermatitis in dogs: a systematic review of randomized controlled trials. Veterinary Dermatology, 21(1), 4-22.
• Olivry, T., Sousa,C.A, (2001), The ACVD task force on canine atopic dermatitis (XX): glucocorticoid pharmacotherapy, Veterinary Immunology and Immunopathology, 81,317-322.
• Olivry, T., Mueller, R. S., & International Task Force on Canine Atopic Dermatitis. (2003). Evidence‐based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Veterinary dermatology, 14(3), 121-146.
• Olivry, T., Dunston, S. M., Rivierre, C., Jackson, H. A., Murphy, K. M., Peters, E., & Dean, G. A. (2003). A randomized controlled trial of misoprostol monotherapy for canine atopic dermatitis: effects on dermal cellularity and cutaneous tumour necrosis factor‐alpha. Veterinary Dermatology, 14(1), 37-46.)
• Oliveira Ramos, F., Malard, P. F., Brunel, H., Paludo, G. R., de Castro, M. B., da Silva, P., & da Cunha Barreto-Vianna, A. R. (2020). Canine atopic dermatitis attenuated by mesenchymal stem cells. Journal of advanced veterinary and animal research, 7(3), 554–565.
• Paterson, S. (2019). Supplementary therapy in canine atopic dermatitis. Companion Animal, 24(8), 400-407. Plevnik Kapun, A., Salobir, J., Levart, A., Tavčar Kalcher, G., Nemec Svete, A., & Kotnik, T. (2014). Vitamin E supplementation in canine atopic dermatitis: improvement of clinical signs and effects on oxidative stress markers. Veterinary Record, 175(22), 560-560.
• Reis, B. P. Z. C. D., Orge, I. D., Sampaio, G. L. D. A., Daltro, S. R. T., Santos, R. R. D., Meira, C. S., Soares, M. B. P. (2021). Mesenchymal Stem cells in the context of canine atopic dermatitis: A Review. Revista Brasileira de Saúde e Produção Animal, 22.
• Reme, C. A., Mondon, A., Calmon, J. P., Poisson, L., Jasmin, P., & Carlotti, D. N. (2004). FC‐40 Efficacy of combined topical therapy with antiallergic shampoo and lotion for the control of signs associated with atopic dermatitis in dogs. Veterinary Dermatology, 15, 33-33.)
• Samara, E. M. I. L., Bialer, M. E. I. R., & Mechoulam, R. A. P. H. A. E. L. (1988). Pharmacokinetics of cannabidiol in dogs. Drug metabolism and disposition, 16(3), 469-472.
• Santoro D., (2019), Therapies in Canine Atopic Dermatitis: An Update, Veterinary Clinics of North America: Small Animal Practice, Vol. 49, Issue 1,9-26.
• Saridomichelakis M.N., Olivry T, (2016), An update on the treatment of canine atopic dermatitis, The Veterinary Journal, Vol 207, 29-37
• Schilling, J., & Mueller, R. S. (2012). Double‐blinded, placebo‐controlled study to evaluate an antipruritic shampoo for dogs with allergic pruritus. Veterinary Record, 171(4), 97-97.
• Sijbrandij, T., Ligtenberg, A. J., Nazmi, K., Veerman, E. C., Bolscher, J. G., & Bikker, F. J. (2017). Effects of lactoferrin derived peptides on simulants of biological warfare agents. World Journal of Microbiology and Biotechnology, 33(1), 1-9.
• Singh, S. K., Dimri, U., Saxena, S. K., & Jadhav, R. K. (2010). Therapeutic management of canine atopic dermatitis by combination of pentoxifylline and PUFAs. Journal of veterinary pharmacology and therapeutics, 33(5), 495-498.
• Souza, C.P., Rosychuk, R.A.W., Contreras, E.T., Schissler, J.R. and Simpson, A.C. (2018), A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Vet Dermatol, 29: 489-e164
• Villatoro, A. J., Hermida‐Prieto, M., Fernández, V., Fariñas, F., Alcoholado, C., Rodríguez‐García, M. I., ... & Becerra, J. (2018). Allogeneic adipose‐derived mesenchymal stem cell therapy in dogs with refractory atopic dermatitis: clinical efficacy and safety. Veterinary Record, 183(21), 654-654.
• Wakshlag, J. J., Schwark, W. S., Deabold, K. A., Talsma, B. N., Cital, S., Lyubimov, A., ... & Zakharov, A. (2020). Pharmacokinetics of cannabidiol, cannabidiolic acid, Δ9-tetrahydrocannabinol, tetrahydrocannabinolic acid and related metabolites in canine serum after dosing with three oral forms of hemp extract. Frontiers in Veterinary Science, 505.
• Yamazaki, C., Rosenkrantz, W., & Griffin, C. (2019). Pilot evaluation of Enterococcus faecium SF68 as adjunctive therapy for oclacitinib‐responsive adult atopic dermatitis in dogs. Journal of Small Animal Practice, 60(8), 499-506.
• Yasukawa K, Saito S, Kubo T, Shibasaki Y, Yamaoka K, Hachimura H, Kuyama T, Amimoto A, Kumata T, Kitahara Y, Takenaka M, Matsumura H, Uno T, Uchino T, Takehara K, Nishida K, Kadoya M, Sato M, Kato K,
• Matsumoto K, Saito S, Shimoda T. (2010) Low-dose recombinant canine interferon-gamma for treatment of canine atopic dermatitis: an open randomized comparative trial of two doses. Vet Dermatol. 21(1):42-49.
• Ohmori, K., Tanaka, A., Makita, Y., Takai, M., Yoshinari, Y., & Matsuda, H. (2010). Pilot evaluation of the efficacy of shampoo treatment with ultrapure soft water for canine pruritus. Veterinary Dermatology, 21(5), 477-483.
• Ohshima‐Terada, Y., Higuchi, Y., Kumagai, T., Hagihara, A., & Nagata, M. (2015). Complementary effect of oral administration of L actobacillus paracasei K 71 on canine atopic dermatitis. Veterinary Dermatology, 26(5), 350-e75.
• Olivry, T., DeBoer, D.J., Favrot, C. et al. (2015),Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Veterinary Research, 11, 210
• Olivry, T., DeBoer, D.J., Favrot, C., Jackson, H.A., Mueller, R.S., Nuttall, T., Prélaud, P. and (2010), Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Veterinary Dermatology, 21, 233-248
• Olivry, T., Foster, A. P., Mueller, R. S., McEwan, N. A., Chesney, C., & Williams, H. C. (2010). Interventions for atopic dermatitis in dogs: a systematic review of randomized controlled trials. Veterinary Dermatology, 21(1), 4-22.
• Olivry, T., Sousa,C.A, (2001), The ACVD task force on canine atopic dermatitis (XX): glucocorticoid pharmacotherapy, Veterinary Immunology and Immunopathology, 81,317-322.
• Olivry, T., Mueller, R. S., & International Task Force on Canine Atopic Dermatitis. (2003). Evidence‐based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Veterinary Dermatology, 14(3), 121-146.
• Olivry, T., Dunston, S. M., Rivierre, C., Jackson, H. A., Murphy, K. M., Peters, E., & Dean, G. A. (2003). A randomized controlled trial of misoprostol monotherapy for canine atopic dermatitis: effects on dermal cellularity and cutaneous tumour necrosis factor‐alpha. Veterinary Dermatology, 14(1), 37-46.)
• Oliveira Ramos, F., Malard, P. F., Brunel, H., Paludo, G. R., de Castro, M. B., da Silva, P., & da Cunha Barreto-Vianna, A. R. (2020). Canine atopic dermatitis attenuated by mesenchymal stem cells. Journal of Advanced Veterinary and Animal Research, 7(3), 554–565.
• Paterson, S. (2019). Supplementary therapy in canine atopic dermatitis. Companion Animal, 24(8), 400-407.
• Plevnik Kapun, A., Salobir, J., Levart, A., Tavčar Kalcher, G., Nemec Svete, A., & Kotnik, T. (2014). Vitamin E supplementation in canine atopic dermatitis: improvement of clinical signs and effects on oxidative stress markers. Veterinary Record, 175(22), 560-560.
• Reis, B. P. Z. C. D., Orge, I. D., Sampaio, G. L. D. A., Daltro, S. R. T., Santos, R. R. D., Meira, C. S., Soares, M. B. P. (2021). Mesenchymal Stem cells in the context of canine atopic dermatitis: A Review. Revista Brasileira de Saude e Producao Animal, 22. 1-12.
• Reme, C. A., Mondon, A., Calmon, J. P., Poisson, L., Jasmin, P., & Carlotti, D. N. (2004). FC‐40 Efficacy of combined topical therapy with antiallergic shampoo and lotion for the control of signs associated with atopic dermatitis in dogs. Veterinary Dermatology, 15, 33-33.
• Samara, E. M. I. L., Bialer, M. E. I. R., & Mechoulam, R. A. P. H. A. E. L. (1988). Pharmacokinetics of cannabidiol in dogs. Drug Metabolism and Disposition, 16(3), 469-472.
• Santoro D., (2019), Therapies in Canine Atopic Dermatitis: An Update, Veterinary Clinics of North America: Small Animal Practice, 49(1), 9-26.
• Saridomichelakis M. N., & Olivry T, (2016), An update on the treatment of canine atopic dermatitis, Veterinary Journal, 207, 29-37
• Schilling, J., & Mueller, R. S. (2012). Double‐blinded, placebo‐controlled study to evaluate an antipruritic shampoo for dogs with allergic pruritus. Veterinary Record, 171(4), 97-97.
• Sijbrandij, T., Ligtenberg, A. J., Nazmi, K., Veerman, E. C., Bolscher, J. G., & Bikker, F. J. (2017). Effects of lactoferrin derived peptides on simulants of biological warfare agents. World Journal of Microbiology and Biotechnology, 33(1), 1-9.
• Singh, S. K., Dimri, U., Saxena, S. K., & Jadhav, R. K. (2010). Therapeutic management of canine atopic dermatitis by combination of pentoxifylline and PUFAs. Journal of Veterinary Pharmacology and Therapeutics, 33(5), 495-498.
• Souza, C.P., Rosychuk, R.A.W., Contreras, E.T., Schissler, J.R. and Simpson, A.C. (2018), A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Veterinary Dermatology, 29, 489-e164
• Villatoro, A. J., Hermida‐Prieto, M., Fernández, V., Fariñas, F., Alcoholado, C., Rodríguez‐García, M. I., ... & Becerra, J. (2018). Allogeneic adipose‐derived mesenchymal stem cell therapy in dogs with refractory atopic dermatitis: clinical efficacy and safety. Veterinary Record, 183(21), 654-654.
• Wakshlag, J. J., Schwark, W. S., Deabold, K. A., Talsma, B. N., Cital, S., Lyubimov, A., Iqbal, A., & Zakharov, A. (2020). Pharmacokinetics of cannabidiol, cannabidiolic acid, Δ9-tetrahydrocannabinol, tetrahydrocannabinolic acid and related metabolites in canine serum after dosing with three oral forms of hemp extract. Frontiers in Veterinary Science, 505.
• Yamazaki, C., Rosenkrantz, W., & Griffin, C. (2019). Pilot evaluation of Enterococcus faecium SF68 as adjunctive therapy for oclacitinib‐responsive adult atopic dermatitis in dogs. Journal of Small Animal Practice, 60(8), 499-506.
• Yasukawa K, Saito S, Kubo T, Shibasaki Y, Yamaoka K, Hachimura H, Kuyama T, Amimoto A, Kumata T, Kitahara Y, Takenaka M, Matsumura H, Uno T, Uchino T, Takehara K, Nishida K, Kadoya M, Sato M, Kato K, Matsumoto K, Saito S, Shimoda T. (2010) Low-dose recombinant canine interferon-gamma for treatment of canine atopic dermatitis: an open randomized comparative trial of two doses. Veterinary Dermatology, 21(1), 42-49.